Precigen (PGEN) Projected to Post Quarterly Earnings on Tuesday

Precigen (NASDAQ:PGEN - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.50 million for the quarter.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The company had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Trading Down 1.5 %

PGEN stock traded down $0.02 during midday trading on Friday, hitting $1.33. The stock had a trading volume of 856,950 shares, compared to its average volume of 1,268,328. The firm has a market cap of $392.57 million, a P/E ratio of -2.42 and a beta of 1.82. The business has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $1.29. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PGEN shares. JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Precigen in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.